378 related articles for article (PubMed ID: 19292062)
21. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
[TBL] [Abstract][Full Text] [Related]
22. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Yamada K; Furusawa S; Saito K; Waga K; Koike T; Arimura H; Aoyagi A; Yamato H; Sakuma H; Tsunogake S
Leukemia; 1995 Jan; 9(1):10-4. PubMed ID: 7531259
[TBL] [Abstract][Full Text] [Related]
23. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
24. [Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
Mori H; Kuriyama K; Tawara M; Danno Y; Fujimoto K; Tushima H; Saito M; Yamamura M; Hata T; Arimura M
Rinsho Ketsueki; 1995 Jul; 36(7):648-56. PubMed ID: 7563592
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
[TBL] [Abstract][Full Text] [Related]
26. [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
Chen YX; Ma XR; Zhang WG; Liu J; Cao XM; He AL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1002-5. PubMed ID: 18928583
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
28. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
29. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
[TBL] [Abstract][Full Text] [Related]
30. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
31. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
32. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
Chen C; Xu W; Yang J
Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
[TBL] [Abstract][Full Text] [Related]
33. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
[TBL] [Abstract][Full Text] [Related]
35. [Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].
Liu H; He GS; Wu DP; Sun AN; Shao ZH; Qian SX; Xiao ZJ; Ma J; Wang SY; Xu XP; Liu T; Jin J; Chen ZC; Fang MY; Chen BA; Xu LP; Shen ZX; Ruan CG
Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(10):689-91. PubMed ID: 22781297
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Bernell P; Kimby E; Hast R
Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
[TBL] [Abstract][Full Text] [Related]
37. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Ganser A; Heil G; Kolbe K; Maschmeyer G; Fischer JT; Bergmann L; Mitrou PS; Heit W; Heimpel H; Huber C
Ann Hematol; 1993 Mar; 66(3):123-5. PubMed ID: 7682447
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
[TBL] [Abstract][Full Text] [Related]
39. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
[TBL] [Abstract][Full Text] [Related]
40. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
Feng X; Lan H; Ruan Y; Li C
Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
